NanoViricides Inc. (NNVC)

[changes_iv]

Yes, I stand corrected "dottore" kazmd65. Thank you. I meant to state once again that the application submitted by Nanoviricides (Jun 10, 2013) to the FDA, for designation of DengueCide TM with Orphan Drug status, should be approved by FDA soon, before Sep 10 2013. Drugs designated with Orphan Drug status are promising developmental drugs and are "fast tracked" to the next "station", Phase I/II. That cGMP pilot plant in Shelton, CT will soon be complete (4Q 2013), commissioned, lit, and humming. Time is money! Dr. Seymour and NNVC's management understand this well.

Dr Seymour (Nanoviricides CEO) answers question (March 2103) after presentation UCLA University School of Medicine:

"This is one of the most prestigious Nanotechnology Institutes in the world. I've been talking to them for the past 4 years. I think they have finally understood the scope and magnitude of the work that he has done. He and I will be meeting with people from a number of different departments such as Chemistry, BioChemistry, Physics, Biophysics etc. I know some of these people from my prior faculty position at the UCLA School of Medicine. The Institute is rich with distinguished scientists and graduate students, some with Master's degrees and many with PhD's. They have expressed a serious interest in collaborating with us on a number of basic science projects that will yield information that the FDA will require. The amount of time and money that we will save is truly incalculable. Whenever you present a new technology to the FDA, having a prestigious Institute and University behind you is extremely valuable. They will also begin to publish papers that will get us the attention we need in the lay press.More information will be forthcoming over the next few months as we continue to move forward."

We have collaborators which are listed about sixteen minutes into the recent NNVC - RedChip video presentation ---

---. The "unlisted" collaborator? UCLA School of Medicine, bring it on! We have management, managing project/activities with collaborators, managing/gathering data on-time, managing/gathering results of animal tox tests, building up the case for DengueCide TM approval which already "...has shown very high effectiveness in animal models of dengue virus infection and also in cell culture studies of dengue virus infection. These animal studies as well as cell culture studies were conducted in the laboratory of Dr. Eva Harris, Professor of Public Health and Infectious Diseases at the University of California, Berkeley. Prof. Harris found that the special laboratory mouse strain AG129 infected with a dengue virus in a lethal challenge ADE-simulation protocol, when left untreated, suffered a 100% fatality rate. In contrast, in the same study, animals treated with NanoViricides' DengueCide TM achieved an unprecedented 50% survival rate."

Once a compound has been granted orphan designation, the odds for approval are high (82%) compared to traditional drugs (35%).

The time from Phase II to market is often shorter for orphan drugs due to shorter and smaller clinical trials and FDA Fast Track designation.

The "Nano-Cides Special" has tracks and each will soon be carrying valued cargo, in a controlled race to the market (2014 - 2015).---

---. Woo-wooo!